ArticleMolecular medicine reports2016
MicroRNA-128 inhibition attenuates myocardial ischemia/reperfusion injury-induced cardiomyocyte apoptosis by the targeted activation of peroxisome proliferator-activated receptor gamma.
Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Restoration of Sestrin 3 Expression Mitigates Cardiac Oxidative Damage in Ischemia-Reperfusion Injury Model.Antioxidants (Basel, Switzerland) · 2025Article
- MicroRNA-specific therapeutic targets and biomarkers of apoptosis following myocardial ischemia-reperfusion injury.Molecular and cellular biochemistry · 2024Review
- QiShenYiQi pill for myocardial collagen metabolism and apoptosis in rats of autoimmune cardiomyopathy.Pharmaceutical biology · 2022Article
- MicroRNA-489 Promotes the Apoptosis of Cardiac Muscle Cells in Myocardial Ischemia-Reperfusion Based on Smart Healthcare.Journal of healthcare engineering · 2022Article
- Effects of Peroxiredoxin 6 and Its Mutants on the Isoproterenol Induced Myocardial Injury in H9C2 Cells and Rats.Oxidative medicine and cellular longevity · 2022Article
- Targeting cardiomyocyte proliferation as a key approach of promoting heart repair after injury.Molecular biomedicine · 2021Review
- Upregulation of miR-128 Mediates Heart Injury by Activating Wnt/β-catenin Signaling Pathway in Heart Failure Mice.Organogenesis · 2021Article
- Downregulation of miR-128 Ameliorates Ang II-Induced Cardiac Remodeling via SIRT1/PIK3R1 Multiple Targets.Oxidative medicine and cellular longevity · 2021Article
- A miRNA's insight into the regenerating heart: a concise descriptive analysis.Heart failure reviews · 2020Review
- TargetingeLife · 2020Article
- Plk2 Regulated by miR-128 Induces Ischemia-Reperfusion Injury in Cardiac Cells.Molecular therapy. Nucleic acids · 2020Article
- MSTN Attenuates Cardiac Hypertrophy through Inhibition of Excessive Cardiac Autophagy by Blocking AMPK /mTOR and miR-128/PPARγ/NF-κB.Molecular therapy. Nucleic acids · 2020Article
- Upregulation of MicroRNA-128 in the Peripheral Blood of Acute Ischemic Stroke Patients is Correlated with Stroke Severity Partially through Inhibition of Neuronal Cell Cycle Reentry.Cell transplantation · 2019Article
- MicroRNAs as Potential Pharmaco-targets in Ischemia-Reperfusion Injury Compounded by Diabetes.Cells · 2019Review
- Loss of microRNA-128 promotes cardiomyocyte proliferation and heart regeneration.Nature communications · 2018Article
- Crosstalk between MicroRNAs and Peroxisome Proliferator-Activated Receptors and Their Emerging Regulatory Roles in Cardiovascular Pathophysiology.PPAR research · 2018Review
- FoxO4 promotes myocardial ischemia-reperfusion injury: the role of oxidative stress-induced apoptosis.American journal of translational research · 2018Article
- MicroRNA-126a-5p enhances myocardial ischemia-reperfusion injury through suppressing Hspb8 expression.Oncotarget · 2017Article
- MicroRNA-128 promotes apoptosis in lung cancer by directly targeting NIMA-related kinase 2.Thoracic cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the effects of microRNA (miR)-128 inhibition on the targeted activation of peroxisome proliferator-activated receptor gamma (PPARG) and on cardiomyocyte apoptosis induced by myocardial ischemia/reperfusion (I/R) injury. In vitro, the expression of PPARG was detected by reverse transcription-quantitative polymerase chain reaction and western blotting in neonatal rat ventricular myocytes (NRVMs) and HEK293 cells transfected with the mimics or inhibitors of miR‑128 or control RNA. Luciferase reporter assays were used to identify whether PPARG is a direct target of miR‑128. In vivo, miR‑128 was knocked down via ear vein injection of antagomir‑128 in a rabbit myocardial I/R injury model. Western blotting investigated the activation of Akt [phosphorylated (p)‑Akt] and the expression of total‑Akt, PPARG and myeloid leukemia cell differentiation protein‑1 (Mcl‑1) in the myocardium. Cardiomyocyte apoptosis was examined with transmission electron microscropy and terminal deoxynucleotidyl transferase dUTP nick end labeling staining. PPARG mRNA and protein were downregulated in NRVMs transfected with miR‑128 mimics, but upregulated by antagomir‑128 compared with control. This indicates that PPARG is a direct miR‑128 target. Activation of Akt (p‑Akt), Mcl‑1 and PPARG expression in the myocardium were increased by miR‑128 inhibition. Furthermore, miR‑128 antagomirs significantly reduced apoptosis in hearts subjected to I/R injury, which was blocked by the PPARG inhibitor GW9662. In conclusion, miR‑128 inhibition attenuated I/R injury‑induced cardiomyocyte apoptosis by the targeted activation of PPARG signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.